First Affirmative Financial Network Acquires New Position in IQVIA Holdings Inc. (NYSE:IQV)

First Affirmative Financial Network bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 931 shares of the medical research company’s stock, valued at approximately $209,000.

Other institutional investors also recently made changes to their positions in the company. Old North State Trust LLC grew its stake in IQVIA by 342.2% during the 1st quarter. Old North State Trust LLC now owns 597 shares of the medical research company’s stock worth $27,000 after buying an additional 462 shares during the last quarter. Hanson & Doremus Investment Management increased its holdings in shares of IQVIA by 300.0% in the 1st quarter. Hanson & Doremus Investment Management now owns 144 shares of the medical research company’s stock worth $29,000 after acquiring an additional 108 shares during the period. AllSquare Wealth Management LLC bought a new stake in IQVIA in the 1st quarter valued at about $36,000. Live Oak Investment Partners acquired a new position in IQVIA during the 4th quarter valued at about $41,000. Finally, Headlands Technologies LLC grew its position in IQVIA by 62.3% in the 1st quarter. Headlands Technologies LLC now owns 224 shares of the medical research company’s stock worth $45,000 after purchasing an additional 86 shares during the last quarter. 86.82% of the stock is owned by institutional investors.

IQVIA Stock Performance

IQV opened at $211.71 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 2.16. The firm has a market cap of $38.77 billion, a PE ratio of 36.44, a P/E/G ratio of 2.15 and a beta of 1.37. The business has a fifty day simple moving average of $220.12 and a 200-day simple moving average of $208.10. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $241.86.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, August 1st. The medical research company reported $2.22 earnings per share for the quarter, beating analysts’ consensus estimates of $2.09 by $0.13. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.70 billion. IQVIA had a return on equity of 30.14% and a net margin of 7.47%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 9.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IQV. Citigroup boosted their price objective on IQVIA from $200.00 to $225.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Barclays raised their price target on IQVIA from $230.00 to $250.00 in a report on Tuesday, June 27th. StockNews.com began coverage on shares of IQVIA in a report on Thursday, August 17th. They issued a “hold” rating for the company. Morgan Stanley raised their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Wednesday, August 2nd. Finally, Stifel Nicolaus upped their price target on shares of IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $252.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.